Literature DB >> 30723043

Contralateral axillary sentinel lymph node drainage in breast cancer: Controversies and management according to the literature. A case report.

R Valhondo-Rama1, C G Wakfie-Corieh2, E A Rodríguez Gallo2, M J Pérez-Castejón2, J M Brenes Sánchez3, M Herrera de la Muela3, J L Carreras-Delgado2.   

Abstract

Lymphoscintigraphy in breast cancer usually shows lymphatic drainage to the ipsilateral axilla. Drainage to extraaxillary or contralateral axillary regions is rare and there is still controversy about its management. Due to the significant clinical impact of an accurate staging, a literature research is made based on a case of a patient with recurrence of left breast cancer with contralateral axillary sentinel lymph node detection, without evidence of lymphatic drainage to other locations.
Copyright © 2018. Publicado por Elsevier España, S.L.U.

Entities:  

Keywords:  Breast cancer; Contralateral; Cáncer de mama; Drenaje extraaxilar; Extraaxillary drainage; Ganglio centinela; Linfogammagrafía; Lymphoscintigraphy; Sentinel node

Mesh:

Year:  2019        PMID: 30723043     DOI: 10.1016/j.remn.2018.11.003

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol (Engl Ed)        ISSN: 2253-8089


  3 in total

1.  Efficacy of the Whole-Course Case Management Model on Compliance and Satisfaction of Breast Cancer Patients with Whole-Course Standardized Treatment.

Authors:  Lijun Jin; Yunyan Zhao; Peng Wang; Ran Zhu; Jie Bai; Jie Li; Xue Jia; Zunyi Wang
Journal:  J Oncol       Date:  2022-06-24       Impact factor: 4.501

2.  Exploring the Prognosis of Breast Cancer with Synchronous Distant Nonregional Lymph Node Metastasis and Establishing a Predictive Model: A Population-Based Study.

Authors:  Hong Lin; Jianxiong Lin; Yanxuan Wu; Guoxi Liang; Jiating Sun; Liming Chen
Journal:  Biomed Res Int       Date:  2022-01-12       Impact factor: 3.411

3.  The Application of Whole-Process Case Management in Patients with Triple-Negative Breast Cancer.

Authors:  Yunyan Zhao; Ran Zhu; Jie Bai; Jie Li; Xue Jia; Peng Wang; Lijun Jin
Journal:  J Oncol       Date:  2022-03-16       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.